Skip to content

Assessment of the prognosis of the patients of connective tissue disease.

Assessment of the prognosis of the patients of connective tissue disease. - Assessment of the prognosis of the patients of connective tissue disease.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000024156
Enrollment
150
Registered
2016-09-26
Start date
2016-09-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis, scleroderma, polymyositis-dermatomyositis, systemic lupus erythematosus, mixed connective tissue disease, Sjogren syndrome, eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, microscopic polyangiitis, IgG4-related disease.

Interventions

None listed

Sponsors

Yamaguchi University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who meet the following of one of the diagnostic criteria. 1) 2010 ACR/EULAR classification criteria for rheumatoid arthritis. 2) 2013 classification criteria for systemic sclerosis 3) Bohan and Peter criteria for polymyositis and dermatomyositis 4) 2012 SLICC classification criteria for systemic lupus erythematosus 5) 2004 Preliminary diagnostic criteria for mixed connective tissue disease proposed by Ministry of Health, Labour and Welfare in Japan. 6) 2012 ACR classification criteria for Sjogren's syndrome 7) 1990 ACR classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis) 8) 1990 ACR classification of Wegener's granulomatosis (granulomatosis and angiitis) 9) 1999 diagnostic criteria for microscopic polyangiitis by Ministry of Health and Welfare in Japan. 10) 2011 Comprehensive diagnostic criteria for IgG4-related disease by Ministry of Health, Labour and Welfare in Japan.

Exclusion criteria

Exclusion criteria: 1) Patients who are judged to be inappropriate as a research subject by the principal investigator or research team members. 2) Patients who are considered to be difficult to obtain a valid consent.

Design outcomes

Primary

MeasureTime frame
Overall survival

Secondary

MeasureTime frame
progression-free survival complications

Countries

Japan

Contacts

Public ContactMakoto Kubo

Yamaguchi University Hospital Internal Medicine 2

mkubo@yamaguchi-u.ac.jp0836-22-2248

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026